(P-108) Ibuzatrelvir Potently Reduced Viral RNA Levels Despite the High Rate of Anti-S Seropositivity: a Post Hoc Analysis of Serology in the Phase 2b Study in Adults Without Risk Factors for Severe COVID-19

Monday, October 20, 2025

12:15 PM - 1:30 PM US ET

Location: Poster Hall B4-B5

Presenting Author(s)

AK

Alex Knutson, Ph.D.

Pfizer
Cambridge, Massachusetts, United States
JS

Justin Smith, M.S.

Pfizer
Groton, Connecticut, United States
SG

Shunjie Guan, PhD in Statistics

Associate Director, Biomarker Statistics
Pfizer
Cambridge, Massachusetts, United States
LC

Luke Chen, MBBS

Pfizer
New York, New York, United States
MM

Mahta Mortezavi, MD

Pfizer
New York, New York, United States
AS

Abigail Sloan, Ph.D.

Pfizer
Cambridge, Massachusetts, United States
AB

Anindita Banerjee, Ph.D.

Pfizer
Cambridge, Massachusetts, United States
Mary Lynn Baniecki, PhD

Head of Infectious Disease for Translational Medicine
Pfizer Inc
Cambridge, Massachusetts, United States
CH

Craig Hyde, Ph.D.

Pfizer
Groton, Connecticut, United States
CA

Charlotte Allerton, PhD

Pfizer
New York, New York, United States
NA

Negar Niki Alami, MD

Pfizer Inc.
Chicago, Illinois, United States